Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma

Cirrincione, Lauren R, Penchala, Sujan Dilly, Scarsi, Kimberly K, Podany, Anthony T, Winchester, Lee C, Back, David J, Khoo, Saye H ORCID: 0000-0002-2769-0967, Fletcher, Courtney V, Siccardi, Marco ORCID: 0000-0002-3539-7867 and Else, Laura J (2018) Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084. pp. 106-112.

[thumbnail of LNG method manuscript v2 FINAL 102017.docx]

Text
LNG method manuscript v2 FINAL 102017.docx - Author Accepted Manuscript
Download (351kB)

Official URL: http://dx.doi.org/10.1016/j.jchromb.2018.03.023

Abstract

Levonorgestrel (LNG) is a synthetic progestin that is available in oral contraceptive tablets, a subdermal implant, and an intrauterine system for contraception. LNG pharmacokinetics are a pivotal determinant of contraceptive efficacy and essential in assessing drug-drug interactions influencing LNG exposure following different routes of LNG administration. A highly sensitive LC-MS/MS method was developed and validated to quantify levonorgestrel in human plasma. Liquid-liquid extraction was utilized with a sample volume of 500 μL to extract levonorgestrel from plasma. Chromatographic separation of LNG was achieved with a Fortis™ C18 (3 μm: 100 mm × 2.1 mm) reverse phase analytical column. The mobile phases consisted of de-ionized water plus 0.1% NH<sub>4</sub>OH (100:0.1%, v/v) (A), and methanol plus 0.1% NH<sub>4</sub>OH (100:0.1%, v/v) (B) delivered as a gradient at a flow rate of 400 μL/min. Detection of LNG and internal standard (D-(-)-norgestrel-d7) was achieved using positive polarity mode monitoring at 313.2-245.2 amu and 320.1-251.2 amu, respectively. The assay was linear over the calibration range of 49.6 to 1500 pg/mL. This method was used to quantify plasma LNG released by subdermal implant in support of a drug interaction study among women with HIV receiving efavirenz- or nevirapine-based antiretroviral therapy.

Item Type:	Article
Uncontrolled Keywords:	LC-MS/MS, Liquid-liquid extraction, Levonorgestrel, Subdermal implant, Plasma
Depositing User:	Symplectic Admin
Date Deposited:	07 Jun 2018 11:43
Last Modified:	14 Feb 2024 01:29
DOI:	10.1016/j.jchromb.2018.03.023
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3022209